This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

SGLT2 inhibitors and kidney stones

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A study (n=20,146) found SGLT-2 inhibitor use associated with lower recurrence of nephrolithiasis than use of a GLP-1 receptor agonist (1924 [105.3 per 1000 person years] vs 853 [156.4 per 1000 person years] events, respectively; adjusted rate ratio 0.67; 95% CI 0.57-0.79; NNT 20) (1):

  • among those with recently active nephrolithiasis, the absolute rate difference was 219 per 1000 person years (NNT of 5)
  • gout recurrence was also lower among SGLT-2 inhibitor users with concomitant gout

The study authors concluded that:

  • benefits associated with SGLT-2 inhibitor for patients with nephrolithiasis in these target trial emulations suggest they may be a useful addition to current treatments to simultaneously manage nephrolithiasis recurrence and comorbidities, including gout

Reference:

  1. McCormick N, Yokose C, Lu N, Wexler D J, Aviña-Zubieta J A, De Vera M A et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studiesBMJ 2024; 387 :e080035

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.